We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+3.29%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$2.76B
AUM Growth
+$170M
Cap. Flow
+$156M
Cap. Flow %
5.64%
Top 10 Hldgs %
29.4%
Holding
140
New
9
Increased
43
Reduced
9
Closed
5

Top Buys

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$48.9M
2
ADPT icon
Adaptive Biotechnologies
ADPT
+$26.6M
3
PODD icon
Insulet
PODD
+$25.1M
4
CHRS icon
Coherus Oncology
CHRS
+$21M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$14.7M

Top Sells

Rank Stock Value
1
WMGI
Wright Medical Group Inc
WMGI
+$29M
2
CVET
Covetrus, Inc. Common Stock
CVET
+$17.8M
3
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$16.4M
4
IFRX icon
InflaRx
IFRX
+$8.5M
5
CMTA
Clementia Pharmaceuticals Inc.
CMTA
+$7.18M

Sector Composition

Rank Sector Weight
1 Healthcare 86.18%
2 Consumer Staples 0.39%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NGM
101
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$5.14M 0.19%
+351,100
New +$5.14M
MGNX icon
102
MacroGenics
MGNX
$257M
$5.09M 0.18%
300,000
– –
GMDA
103
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
$5.08M 0.18%
+1,000,000
New +$7.85M
MNTA
104
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$4.98M 0.18%
400,000
– –
CHMA
105
DELISTED
Chiasma, Inc. Common Stock
CHMA
$4.86M 0.18%
650,000
– –
ACRS icon
106
Aclaris Therapeutics
ACRS
$869M
$4.44M 0.16%
2,028,000
+328,000
+19% +$1.79M
AKRO
107
DELISTED
Akero Therapeutics
AKRO
$4.31M 0.16%
+225,000
New +$4.26M
CGEN icon
108
Compugen
CGEN
$228M
$4.22M 0.15%
1,100,000
– –
ACET icon
109
Adicet Bio
ACET
$74.7M
$4.08M 0.15%
3,571
– –
MYOV
110
DELISTED
Myovant Sciences Ltd.
MYOV
$4.07M 0.15%
450,000
+102,500
+29% +$1.53M
ICPT
111
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$3.98M 0.14%
+50,000
New +$4.48M
LJPC
112
DELISTED
La Jolla Pharmaceutical Company
LJPC
$3.93M 0.14%
425,000
+147,764
+53% +$1.11M
NBRV
113
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$3.89M 0.14%
6,400
– –
CLVS
114
DELISTED
Clovis Oncology, Inc.
CLVS
$3.81M 0.14%
256,000
– –
ADAP
115
DELISTED
Adaptimmune Therapeutics
ADAP
$3.52M 0.13%
875,000
+75,000
+9% +$306K
ARVN icon
116
Arvinas
ARVN
$572M
$3.3M 0.12%
150,000
– –
FPRX
117
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$3.17M 0.11%
526,100
+21,100
+4% +$202K
DVAX
118
DELISTED
Dynavax Technologies
DVAX
$2.59M 0.09%
650,000
+270,000
+71% +$1.57M
CORV
119
DELISTED
Correvio Pharma Corp. Ordinary Shares (Canada)
CORV
$2.59M 0.09%
1,200,000
– –
PRTK
120
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$1.8M 0.07%
450,000
– –
CRVS icon
121
Corvus Pharmaceuticals
CRVS
$1.17B
$1.5M 0.05%
400,000
– –
KLDO
122
DELISTED
Kaleido Biosciences, Inc. Common Stock
KLDO
$1.16M 0.04%
100,050
– –
NVAX icon
123
Novavax
NVAX
$1.31B
$952K 0.03%
162,500
– –
CVET
124
DELISTED
Covetrus, Inc. Common Stock
CVET
$788K 0.03%
32,231
-617,769
-95% -$17.8M
HRTX icon
125
Heron Therapeutics
HRTX
$92.9M
$558K 0.02%
30,000
-320,000
-91% -$6.39M
2 3 4
5
6

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q2 2019 Portfolio in Review

As of Q2 2019, Rock Springs Capital Management held 140 positions worth $2.76B, up 6.6% from $2.59B the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Rock Springs Capital Management deployed $156M of net new capital in Q2 2019, opening 9 new positions and adding to 43 existing holdings. Its largest new stake was Bristol-Myers Squibb: 1,050,000 shares worth $47.6M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 85% a quarter earlier, followed by Consumer Staples.

On the sell side, the largest reduction was Covetrus, Inc. Common Stock, an estimated $17.8M trimmed.

  • Rock Springs Capital Management's largest Q2 2019 buy was Bristol-Myers Squibb: 1,050,000 shares worth $47.6M.
  • Rock Springs Capital Management added most to Coherus Oncology in Q2 2019, an estimated $21M increase.
  • Rock Springs Capital Management's biggest Q2 2019 reduction was Covetrus, Inc. Common Stock, cutting an estimated $17.8M.
  • Rock Springs Capital Management fully exited Wright Medical Group Inc in Q2 2019, selling an estimated $29M.
  • Rock Springs Capital Management's ten largest holdings make up 29% of its $2.76B portfolio in Q2 2019.
  • Rock Springs Capital Management opened 9 new positions and closed 5 in Q2 2019.
  • Rock Springs Capital Management's portfolio value rose 6.6% quarter-over-quarter to $2.76B.

Based on Rock Springs Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.